Co-Authors
This is a "connection" page, showing publications co-authored by Tom Shimabukuro and John Su.
Connection Strength
2.563
-
Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021 Mar 16; 325(11):1101-1102.
Score: 0.935
-
Safety of Second-Dose Single-Antigen Varicella Vaccine. Pediatrics. 2017 Mar; 139(3).
Score: 0.703
-
Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021. MMWR Morb Mortal Wkly Rep. 2021 May 07; 70(18):680-684.
Score: 0.236
-
First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021 Feb 26; 70(8):283-288.
Score: 0.233
-
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 13; 70(32):1094-1099.
Score: 0.060
-
COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 06; 70(31):1053-1058.
Score: 0.060
-
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 09; 70(27):977-982.
Score: 0.060
-
US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. JAMA. 2021 06 22; 325(24):2448-2456.
Score: 0.060
-
U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines. Vaccine. 2021 06 23; 39(28):3666-3677.
Score: 0.059
-
Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination - Five U.S. Mass Vaccination Sites, April 2021. MMWR Morb Mortal Wkly Rep. 2021 May 07; 70(18):685-688.
Score: 0.059
-
Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018. MMWR Morb Mortal Wkly Rep. 2019 Feb 01; 68(4):91-94.
Score: 0.050
-
Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015. Hum Vaccin Immunother. 2018; 14(8):1963-1969.
Score: 0.048